Royal Bank of Canada
RPRX

Royal Bank of Canada’s Repros Therapeutics Inc. RPRX Stock Holding History

Royal Bank of Canada’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-40,100
Closed -$734K – 6526
2013
Q4 		$734K Buy
40,100
+30,100
+301% +$568K ﹤0.01% 3108
2013
Q3 		$268K Buy
+10,000
New +$214K ﹤0.01% 3879

Other funds holding RPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
AIA
Allegis Investment Advisors Idaho Falls, Idaho $326M AUM 10.36% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Royal Bank of Canada's RPRX Position: Q4 2016 in Review

Royal Bank of Canada sold out of Repros Therapeutics Inc. (RPRX) in Q4 2016, closing a stake of 900 shares — an estimated $2K sold.

Royal Bank of Canada first reported a position in RPRX in Q3 2014 and held it in 4 quarters. The position peaked at $297K in Q3 2014. 43 funds tracked by Wall St. Rank hold RPRX as of Q4 2016.

  • Royal Bank of Canada reported no remaining Repros Therapeutics Inc. position as of Q4 2016 after selling out during the quarter.
  • Royal Bank of Canada sold 900 Repros Therapeutics Inc. shares in Q4 2016, an estimated $2K.
  • Royal Bank of Canada first reported a position in Repros Therapeutics Inc. in Q3 2014 and held it in 4 quarters.
  • Royal Bank of Canada's Repros Therapeutics Inc. position peaked at $297K in Q3 2014.
  • 43 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q4 2016.

Based on Royal Bank of Canada's 13F filing for Q4 2016, filed 14 Feb 2017.